HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

APTR is a prognostic marker in cirrhotic patients with portal hypertension during TIPS procedure.

Abstract
Portal hypertension is a major cause of mortality and morbidity in cirrhotic patients. In this study, we aimed to analyze the clinical characteristics of Alu-mediated p21 transcriptional regulator (APTR) during transjugular intrahepatic portosystemic shunt (TIPS) procedure. Portal and hepatic venous blood was drawn from 84 patients with liver cirrhosis and portal hypertension before and after TIPS treatment. Then, we detected biochemical, hemodynamic parameters and APTR expression before and after TIPS treatment. Indeed, TIPS treatment could markedly ameliorate the serum blood urea nitrogen (BUN) level and portal vein hemodynamics in cirrhotic patients. We found that portal venous levels of APTR was significantly decreased after TIPS treatment and its aberrant expression levels were positively correlated with Model for End Stage Liver Disease (MELD), portal hepatic venous pressure gradient (PHPG) in patients. Higher APTR expression in portal vein was associated with poor prognosis. APTR level in portal vein was an independent predictors of mortality. Our data indicated that APTR may serve as a novel biomarker for cirrhotic patients with portal hypertension before and after receiving TIPS.
AuthorsShanshan Yu, Yanhua Qi, Jue Jiang, Hua Wang, Qi Zhou
JournalGene (Gene) Vol. 645 Pg. 30-33 (Mar 01 2018) ISSN: 1879-0038 [Electronic] Netherlands
PMID29274906 (Publication Type: Journal Article)
CopyrightCopyright © 2017 Elsevier B.V. All rights reserved.
Chemical References
  • Biomarkers
  • RNA, Long Noncoding
  • long non-coding RNA APTR, human
Topics
  • Biomarkers (blood)
  • Blood Urea Nitrogen
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Hypertension, Portal (blood, genetics, surgery)
  • Liver Cirrhosis (blood, complications, genetics, surgery)
  • Male
  • Portasystemic Shunt, Transjugular Intrahepatic
  • Prognosis
  • RNA, Long Noncoding (blood)
  • Survival Analysis
  • Treatment Outcome
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: